Research programme: anti-tau antibodies - Eli Lilly

Drug Profile

Research programme: anti-tau antibodies - Eli Lilly

Alternative Names: AT 8 antibody; DA 9 antibody; MC 1 antibody; PHF 1 antibody

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 16 Jul 2017 Updated pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2017)
  • 12 Jul 2017 Preclinical trials in Alzheimer's disease in USA (Parenteral) before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top